Episode Details

This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE.  Great to see a new drug in this disease state; interesting to think through how these trials played out.  Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback!